Logo image of CNS

COHEN & STEERS INC (CNS) Stock Fundamental Analysis

USA - New York Stock Exchange - NYSE:CNS - US19247A1007 - Common Stock

62.72 USD
-0.5 (-0.79%)
Last: 12/31/2025, 3:59:09 PM
Fundamental Rating

6

Overall CNS gets a fundamental rating of 6 out of 10. We evaluated CNS against 235 industry peers in the Capital Markets industry. CNS has an excellent profitability rating, but there are some minor concerns on its financial health. CNS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

CNS had positive earnings in the past year.
In the past year CNS has reported a negative cash flow from operations.
In the past 5 years CNS has always been profitable.
Each year in the past 5 years CNS had a positive operating cash flow.
CNS Yearly Net Income VS EBIT VS OCF VS FCFCNS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

1.2 Ratios

CNS's Return On Assets of 20.48% is amongst the best of the industry. CNS outperforms 97.87% of its industry peers.
CNS's Return On Equity of 29.83% is amongst the best of the industry. CNS outperforms 95.74% of its industry peers.
Looking at the Return On Invested Capital, with a value of 24.24%, CNS belongs to the top of the industry, outperforming 98.30% of the companies in the same industry.
CNS had an Average Return On Invested Capital over the past 3 years of 28.30%. This is significantly above the industry average of 7.07%.
The 3 year average ROIC (28.30%) for CNS is well above the current ROIC(24.24%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 20.48%
ROE 29.83%
ROIC 24.24%
ROA(3y)20.51%
ROA(5y)25.29%
ROE(3y)38.03%
ROE(5y)48.18%
ROIC(3y)28.3%
ROIC(5y)38.19%
CNS Yearly ROA, ROE, ROICCNS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

1.3 Margins

With a decent Profit Margin value of 29.73%, CNS is doing good in the industry, outperforming 75.74% of the companies in the same industry.
CNS's Profit Margin has declined in the last couple of years.
CNS has a Operating Margin of 33.83%. This is in the better half of the industry: CNS outperforms 65.53% of its industry peers.
CNS's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 88.60%, CNS belongs to the top of the industry, outperforming 92.77% of the companies in the same industry.
CNS's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 33.83%
PM (TTM) 29.73%
GM 88.6%
OM growth 3Y-9.18%
OM growth 5Y-3.03%
PM growth 3Y-6.88%
PM growth 5Y-2.25%
GM growth 3Y0.74%
GM growth 5Y0.55%
CNS Yearly Profit, Operating, Gross MarginsCNS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, CNS has more shares outstanding
CNS has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CNS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CNS Yearly Shares OutstandingCNS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CNS Yearly Total Debt VS Total AssetsCNS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

CNS has an Altman-Z score of 8.90. This indicates that CNS is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of CNS (8.90) is better than 93.19% of its industry peers.
CNS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.9
ROIC/WACCN/A
WACCN/A
CNS Yearly LT Debt VS Equity VS FCFCNS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.3 Liquidity

CNS has a Current Ratio of 0.79. This is a bad value and indicates that CNS is not financially healthy enough and could expect problems in meeting its short term obligations.
CNS has a Current ratio of 0.79. This is in the lower half of the industry: CNS underperforms 63.83% of its industry peers.
CNS has a Quick Ratio of 0.79. This is a bad value and indicates that CNS is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of CNS (0.79) is worse than 63.40% of its industry peers.
CNS does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 0.79
Quick Ratio 0.79
CNS Yearly Current Assets VS Current LiabilitesCNS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 8.87% over the past year.
CNS shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 2.50% yearly.
The Revenue has grown by 11.13% in the past year. This is quite good.
CNS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.72% yearly.
EPS 1Y (TTM)8.87%
EPS 3Y-10.08%
EPS 5Y2.5%
EPS Q2Q%5.19%
Revenue 1Y (TTM)11.13%
Revenue growth 3Y-3.95%
Revenue growth 5Y4.72%
Sales Q2Q%6.39%

3.2 Future

CNS is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.68% yearly.
Based on estimates for the next years, CNS will show a small growth in Revenue. The Revenue will grow by 7.21% on average per year.
EPS Next Y4.56%
EPS Next 2Y8.37%
EPS Next 3Y8.1%
EPS Next 5Y7.68%
Revenue Next Year7.42%
Revenue Next 2Y8.4%
Revenue Next 3Y7.58%
Revenue Next 5Y7.21%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CNS Yearly Revenue VS EstimatesCNS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
CNS Yearly EPS VS EstimatesCNS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1 2 3 4 5

3

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 20.43, CNS is valued on the expensive side.
CNS's Price/Earnings ratio is in line with the industry average.
When comparing the Price/Earnings ratio of CNS to the average of the S&P500 Index (26.77), we can say CNS is valued slightly cheaper.
CNS is valuated rather expensively with a Price/Forward Earnings ratio of 18.23.
The rest of the industry has a similar Price/Forward Earnings ratio as CNS.
The average S&P500 Price/Forward Earnings ratio is at 23.35. CNS is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 20.43
Fwd PE 18.23
CNS Price Earnings VS Forward Price EarningsCNS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CNS indicates a somewhat cheap valuation: CNS is cheaper than 79.15% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 15.77
CNS Per share dataCNS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CNS does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of CNS may justify a higher PE ratio.
PEG (NY)4.48
PEG (5Y)8.18
EPS Next 2Y8.37%
EPS Next 3Y8.1%

4

5. Dividend

5.1 Amount

CNS has a Yearly Dividend Yield of 3.92%.
Compared to an average industry Dividend Yield of 6.65, CNS has a dividend in line with its industry peers.
CNS's Dividend Yield is rather good when compared to the S&P500 average which is at 2.00.
Industry RankSector Rank
Dividend Yield 3.92%

5.2 History

The dividend of CNS decreases each year by -7.12%.
CNS has paid a dividend for at least 10 years, which is a reliable track record.
The dividend of CNS decreased in the last 3 years.
Dividend Growth(5Y)-7.12%
Div Incr Years2
Div Non Decr Years2
CNS Yearly Dividends per shareCNS Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1 2 3

5.3 Sustainability

CNS pays out 76.25% of its income as dividend. This is not a sustainable payout ratio.
DP76.25%
EPS Next 2Y8.37%
EPS Next 3Y8.1%
CNS Yearly Income VS Free CF VS DividendCNS Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
CNS Dividend Payout.CNS Dividend Payout, showing the Payout Ratio.CNS Dividend Payout.PayoutRetained Earnings

COHEN & STEERS INC

NYSE:CNS (12/31/2025, 3:59:09 PM)

62.72

-0.5 (-0.79%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)10-16 2025-10-16/amc
Earnings (Next)01-20 2026-01-20/amc
Inst Owners58.72%
Inst Owner Change-5.95%
Ins Owners22.81%
Ins Owner Change3.3%
Market Cap3.20B
Revenue(TTM)552.10M
Net Income(TTM)164.16M
Analysts48
Price Target78.54 (25.22%)
Short Float %6.31%
Short Ratio4
Dividend
Industry RankSector Rank
Dividend Yield 3.92%
Yearly Dividend2.39
Dividend Growth(5Y)-7.12%
DP76.25%
Div Incr Years2
Div Non Decr Years2
Ex-Date11-10 2025-11-10 (0.62)
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.39%
Min EPS beat(2)-4.27%
Max EPS beat(2)3.48%
EPS beat(4)1
Avg EPS beat(4)-0.86%
Min EPS beat(4)-4.27%
Max EPS beat(4)3.48%
EPS beat(8)3
Avg EPS beat(8)-0.49%
EPS beat(12)5
Avg EPS beat(12)0.41%
EPS beat(16)9
Avg EPS beat(16)1.94%
Revenue beat(2)1
Avg Revenue beat(2)-0.16%
Min Revenue beat(2)-1.18%
Max Revenue beat(2)0.85%
Revenue beat(4)2
Avg Revenue beat(4)-2.44%
Min Revenue beat(4)-11.33%
Max Revenue beat(4)1.91%
Revenue beat(8)3
Avg Revenue beat(8)-1.39%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.35%
PT rev (3m)-1.28%
EPS NQ rev (1m)0%
EPS NQ rev (3m)3.13%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.87%
Revenue NQ rev (1m)-0.14%
Revenue NQ rev (3m)2.7%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)0.33%
Valuation
Industry RankSector Rank
PE 20.43
Fwd PE 18.23
P/S 5.79
P/FCF N/A
P/OCF N/A
P/B 5.81
P/tB 6.03
EV/EBITDA 15.77
EPS(TTM)3.07
EY4.89%
EPS(NY)3.44
Fwd EY5.49%
FCF(TTM)-1.84
FCFYN/A
OCF(TTM)-1.7
OCFYN/A
SpS10.82
BVpS10.79
TBVpS10.39
PEG (NY)4.48
PEG (5Y)8.18
Graham Number27.3
Profitability
Industry RankSector Rank
ROA 20.48%
ROE 29.83%
ROCE 31.59%
ROIC 24.24%
ROICexc 29.06%
ROICexgc 32.58%
OM 33.83%
PM (TTM) 29.73%
GM 88.6%
FCFM N/A
ROA(3y)20.51%
ROA(5y)25.29%
ROE(3y)38.03%
ROE(5y)48.18%
ROIC(3y)28.3%
ROIC(5y)38.19%
ROICexc(3y)52.58%
ROICexc(5y)66.96%
ROICexgc(3y)63.61%
ROICexgc(5y)82.87%
ROCE(3y)36.88%
ROCE(5y)49.77%
ROICexgc growth 3Y-36.94%
ROICexgc growth 5Y-14.2%
ROICexc growth 3Y-34.4%
ROICexc growth 5Y-13.57%
OM growth 3Y-9.18%
OM growth 5Y-3.03%
PM growth 3Y-6.88%
PM growth 5Y-2.25%
GM growth 3Y0.74%
GM growth 5Y0.55%
F-Score5
Asset Turnover0.69
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 63.99%
Cap/Sales 1.34%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.79
Quick Ratio 0.79
Altman-Z 8.9
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)429.54%
Cap/Depr(5y)277.84%
Cap/Sales(3y)4.88%
Cap/Sales(5y)3.14%
Profit Quality(3y)59.63%
Profit Quality(5y)81.14%
High Growth Momentum
Growth
EPS 1Y (TTM)8.87%
EPS 3Y-10.08%
EPS 5Y2.5%
EPS Q2Q%5.19%
EPS Next Y4.56%
EPS Next 2Y8.37%
EPS Next 3Y8.1%
EPS Next 5Y7.68%
Revenue 1Y (TTM)11.13%
Revenue growth 3Y-3.95%
Revenue growth 5Y4.72%
Sales Q2Q%6.39%
Revenue Next Year7.42%
Revenue Next 2Y8.4%
Revenue Next 3Y7.58%
Revenue Next 5Y7.21%
EBIT growth 1Y15.71%
EBIT growth 3Y-12.76%
EBIT growth 5Y1.55%
EBIT Next Year11.2%
EBIT Next 3Y14.28%
EBIT Next 5Y13.32%
FCF growth 1Y-175.84%
FCF growth 3Y-29.26%
FCF growth 5Y-9.31%
OCF growth 1Y-150.56%
OCF growth 3Y-26.44%
OCF growth 5Y-7.32%

COHEN & STEERS INC / CNS FAQ

What is the ChartMill fundamental rating of COHEN & STEERS INC (CNS) stock?

ChartMill assigns a fundamental rating of 6 / 10 to CNS.


Can you provide the valuation status for COHEN & STEERS INC?

ChartMill assigns a valuation rating of 3 / 10 to COHEN & STEERS INC (CNS). This can be considered as Overvalued.


Can you provide the profitability details for COHEN & STEERS INC?

COHEN & STEERS INC (CNS) has a profitability rating of 8 / 10.


What are the PE and PB ratios of COHEN & STEERS INC (CNS) stock?

The Price/Earnings (PE) ratio for COHEN & STEERS INC (CNS) is 20.43 and the Price/Book (PB) ratio is 5.81.


What is the expected EPS growth for COHEN & STEERS INC (CNS) stock?

The Earnings per Share (EPS) of COHEN & STEERS INC (CNS) is expected to grow by 4.56% in the next year.